Profile data is unavailable for this security.
About the company
OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.
- Revenue in AUD (TTM)387.46k
- Net income in AUD-12.38m
- Incorporated2005
- Employees2.00
- LocationOncosil Medical LtdLevel 57 Eden Park Drive, Macquarie ParkMACQUARIE 2113AustraliaAUS
- Phone+61 28935-9629
- Fax+61 29221-8535
- Websitehttp://www.oncosil.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Little Green Pharma Ltd | 25.63m | -8.15m | 25.35m | -- | -- | 0.3263 | -- | 0.9889 | -0.0272 | -0.0272 | 0.0856 | 0.2574 | 0.2772 | 1.05 | 12.29 | -- | -8.82 | -- | -9.74 | -- | 53.18 | -- | -31.81 | -- | 1.39 | -18.90 | 0.0624 | -- | 29.07 | -- | 4.72 | -- | -- | -- |
| Syntara Ltd | 5.43m | -13.67m | 42.59m | 107.00 | -- | 8.42 | -- | 7.85 | -0.0157 | -0.016 | 0.0057 | 0.0039 | 0.3155 | -- | 0.7918 | -- | -79.44 | -30.68 | -130.63 | -40.26 | -- | -- | -251.77 | -74.66 | -- | -484.90 | 0.0474 | -- | -7.92 | -15.43 | -1.77 | -- | -62.79 | -- |
| Vitura Health Ltd | 123.87m | 3.51m | 43.77m | 121.00 | 12.32 | 1.13 | 8.96 | 0.3533 | 0.0062 | 0.0062 | 0.2165 | 0.0674 | 2.10 | 15.04 | 10.74 | -- | 5.50 | 13.50 | 7.70 | 18.51 | 27.63 | 32.41 | 2.62 | 6.19 | 1.11 | 30.48 | 0.2228 | -- | 5.56 | -- | -74.57 | -- | 155.80 | -- |
| Starpharma Holdings Ltd | 9.76m | -8.17m | 43.82m | 50.00 | -- | 1.54 | -- | 4.49 | -0.0198 | -0.0198 | 0.0237 | 0.0682 | 0.2195 | 0.244 | 1.20 | -- | -18.37 | -27.20 | -24.10 | -33.05 | 93.52 | 77.48 | -83.69 | -269.74 | 4.58 | -- | 0.1115 | -- | 131.84 | 29.10 | 47.79 | -- | -22.29 | -- |
| Oncosil Medical Ltd | 387.46k | -12.38m | 45.41m | 2.00 | -- | 8.71 | -- | 117.19 | -0.0056 | -0.0056 | 0.0002 | 0.0014 | 0.0435 | -- | 0.2937 | -- | -138.79 | -68.47 | -170.28 | -78.28 | -256.87 | -- | -3,193.94 | -800.23 | -- | -38.98 | 0.0152 | -- | -9.95 | -36.76 | -9.10 | -- | -- | -- |
| Medical Developments International Ltd | 33.15m | -40.99m | 50.70m | 68.00 | -- | 0.8718 | -- | 1.53 | -0.4627 | -0.4627 | 0.3741 | 0.5162 | 0.4131 | 1.02 | 4.14 | -- | -51.09 | -15.81 | -60.56 | -17.79 | 73.50 | 70.98 | -123.66 | -52.49 | 1.82 | -- | 0.0476 | -- | 2.51 | 9.22 | -630.83 | -- | -20.32 | -- |
| Next Science Ltd | 34.20m | -19.81m | 56.97m | -- | -- | 5.48 | -- | 1.67 | -0.0738 | -0.0738 | 0.1255 | 0.0356 | 1.97 | 5.34 | 8.04 | -- | -113.88 | -74.40 | -168.92 | -90.31 | 78.83 | 76.98 | -57.93 | -128.26 | 1.96 | -- | 0.1045 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Washington H. Soul Pattinson & Co. Ltd. (Invt Mgmt)as of 26 Jul 2024 | 385.71m | 10.19% |
